Dissecting p53 tumor suppressor functions in vivo

被引:404
作者
Schmitt, CA
Fridman, JS
Yang, M
Baranov, E
Hoffman, RM
Lowe, SW
机构
[1] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA
[2] AntiCanc Inc, San Diego, CA 92111 USA
关键词
D O I
10.1016/S1535-6108(02)00047-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although the p53 tumor suppressor acts in a plethora of processes that influence cellular proliferation and survival, it remains unclear which p53 functions are essential for tumor suppression and, as a consequence, are selected against during tumor development. Using a mouse model harboring primary, genetically modified myc-driven lymphomas, we show that disruption of apoptosis downstream of p53 by Bcl2 or a dominant-negative caspase 9 confers-like p53 loss-a selective advantage, and completely alleviates pressure to inactivate p53 during lymphomagenesis. Despite their p53-null-like aggressive phenotype, apoptosis-defective lymphomas that retain intact p53 genes do not display the checkpoint defects and gross aneuploidy that are characteristic of p53 mutant tumors. Therefore, apoptosis is the only p53 function selected against during lymphoma development, whereas defective cell-cycle checkpoints and aneuploidy are mere byproducts of p53 loss.
引用
收藏
页码:289 / 298
页数:10
相关论文
共 46 条
  • [11] ELSON A, 1995, ONCOGENE, V11, P181
  • [12] Proliferation, cell cycle and apoptosis in cancer
    Evan, GI
    Vousden, KH
    [J]. NATURE, 2001, 411 (6835) : 342 - 348
  • [13] Oncogene-dependent apoptosis is mediated by caspase-9
    Fearnhead, HO
    Rodriguez, J
    Govek, EE
    Guo, WJ
    Kobayashi, R
    Hannon, G
    Lazebnik, YA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (23) : 13664 - 13669
  • [14] Cytochrome c depletion upon expression of Bcl-XS
    Fridman, JS
    Parsels, J
    Rehemtulla, A
    Maybaum, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (06) : 4205 - 4210
  • [15] P53 MUTATIONS IN HUMAN LYMPHOID MALIGNANCIES - ASSOCIATION WITH BURKITT-LYMPHOMA AND CHRONIC LYMPHOCYTIC-LEUKEMIA
    GAIDANO, G
    BALLERINI, P
    GONG, JZ
    INGHIRAMI, G
    NERI, A
    NEWCOMB, EW
    MAGRATH, IT
    KNOWLES, DM
    DALLAFAVERA, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (12) : 5413 - 5417
  • [16] Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development
    Gao, YJ
    Ferguson, DO
    Xie, W
    Manis, JP
    Sekiguchi, J
    Frank, KM
    Chaudhuri, J
    Horner, J
    DePinho, RA
    Alt, FW
    [J]. NATURE, 2000, 404 (6780) : 897 - 900
  • [17] Apoptosis inhibitor as a suppressor of tumor progression:: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor
    Gurova, KV
    Kwek, SSS
    Koman, IE
    Komarov, AP
    Kandel, E
    Nikiforov, MA
    Gudkov, AV
    [J]. CANCER BIOLOGY & THERAPY, 2002, 1 (01) : 39 - 44
  • [18] IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools
    Hainaut, P
    Hernandez, T
    Robinson, A
    Rodriguez-Tome, P
    Flores, T
    Hollstein, M
    Harris, CC
    Montesano, R
    [J]. NUCLEIC ACIDS RESEARCH, 1998, 26 (01) : 205 - 213
  • [19] Molecular biology of Burkitt's lymphoma
    Hecht, JL
    Aster, JC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) : 3707 - 3721
  • [20] GENOMIC INSTABILITY IN NEOPLASIA
    HONCHEL, R
    HALLING, KC
    THIBODEAU, SN
    [J]. SEMINARS IN CELL BIOLOGY, 1995, 6 (01): : 45 - 52